Evidence map›Paper›PMID 15829574›Full record

Trial reportAnnals of the rheumatic diseases2005

Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial.

J Fransen, H Bernelot Moens, I Speyer, P L C M van Riel

Registry-linked trialAbstract readClinical TrialMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of the rheumatic diseases, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02260778 (Treat-to-target in RA), which is not on this map. Cited by 57 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02260778 nacompletednot on this mapstarted 2014, after this paper: background citation

Treat-to-target in RA: Collaboration To Improve adOption and adhereNce (TRACTION)

TypeinterventionalSponsorBrigham and Women's HospitalRan2014 to 2024Enrolled11ConditionsArthritis, RheumatoidArmsLearning Collaborative
3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Guideline
  4. Guideline
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Observational
  19. Article
  20. Challenges in Implementing Treat-to-Target Strategies in Rheumatology.Rheumatic diseases clinics of North America · 2019
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

J FransenDepartment of Rheumatology, University Medical Centre Nijmegen, PO Box 9101, NL-6500 HB Nijmegen, Netherlands. j.fransen@reuma.umcn.nl
H Bernelot Moens
I Speyer
P L C M van Riel

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo test the efficacy of standardised monitoring using the disease activity index DAS28 versus usual care on disease modifying antirheumatic drug (DMARD) prescription and disease activity in rheumatoid arthritis.

methodsA 24 week cluster randomised trial. Rheumatology outpatient centres were randomised to systematic monitoring of disease activity using the DAS28 (12 centres, 205 patients) or usual care (12 centres, 179 patients). The aim for the DAS group was to reach a DAS28 score of < or =3.2 by changes in DMARD treatment, at the discretion of the rheumatologist and the patient.

resultsAt baseline, disease activity was the same in both groups, with an overall mean (SD) DAS28 of 4.5 (1.2); 13% of the patients had a DAS28 of < or =3.2. At 24 weeks, 31% of patients in the DAS group had a DAS28 < or =3.2, while in the usual care centres this was 16% (p = 0.028). DMARDs were changed on average in 18% of visits in the DAS centres; in the 12 usual care centres they were changed on 8% of the visits (p = 0.013). The doses of methotrexate, sulfasalazine, and corticosteroids appeared to be higher in the DAS centres than in the usual care centres, but the differences were not significant.

conclusionsIn daily practice, systematic monitoring of disease activity in rheumatoid arthritis may lead to more changes in DMARD treatment, resulting in a larger number of patients with low disease activity.

Indexed as

Adrenal Cortex HormonesAgedAnti-Inflammatory Agents, Non-SteroidalAntirheumatic AgentsArthritis, RheumatoidDrug Administration ScheduleDrug MonitoringFemaleHumansMaleMethotrexateMiddle AgedPatient CompliancePrednisoneSeverity of Illness IndexSulfasalazineAdrenal Cortex HormonesAnti-Inflammatory Agents, Non-SteroidalAntirheumatic AgentsMethotrexatePrednisoneSulfasalazine

Identifiers

PMID15829574
PMCPMC1755664

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.